Fractyl Health Inc (NAS:GUTS)

Q1 2026 Fractyl Health Inc Earnings Call Transcript

May 12, 2026 / 08:30 PM GMT

Release Date Price: $0.734 (-4.55%)

Transcript 10-Q8-K

Key Points

Positve

Fractyl Health Inc (GUTS) has made significant progress with its RUVIDA pivotal trial, completing randomizations with over 300 participants across more than 30 sites in the U.S.
The company has received favorable FDA feedback on its de novo classification request, confirming RUVIDA's safety profile as moderate-risk.
Fractyl Health Inc (GUTS) has a strong financial position, with a cash runway extending into early 2027, allowing them to reach pivotal data without a planned capital raise.
The company is actively building a commercial path for RUVIDA, with favorable market dynamics due to the growing number of GLP-1 initiators and potential CMS reimbursement pathways.
Fractyl Health Inc (GUTS) is advancing its REJUVA gene therapy platform, having received authorization from EU regulatory authorities to initiate a Phase 1/2 study, marking a significant step in clinical development.

Negative

The company faces the challenge of addressing post-GLP-1 weight regain, a significant issue for patients discontinuing GLP-1 therapy.
There are uncertainties related to the regulatory approval process, particularly concerning the de novo submission and the need for comprehensive data to support it.
Fractyl Health Inc (GUTS) reported a negative adjusted EBITDA of $18 million for Q1 2026, indicating ongoing financial losses despite reduced operating expenses.
The company has not yet approached the FDA regarding the REJUVA platform, indicating potential delays in U.S. regulatory progress.
Fractyl Health Inc (GUTS) is reliant on successful pivotal trial outcomes and regulatory approvals to achieve commercial success, which carries inherent risks and uncertainties.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GUTS.OQ - Fractyl Health Inc
Q1 2026 Fractyl Health Inc Earnings Call
May 12, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, and welcome to Fractal's Health First Quarter 2026 Financial Results and Business Update Call.

As a reminder, this conference call is being recorded. At this time, all participants are in listen-only mode. There will be a Q&A session following management's prepared remarks.

I'll now turn the call over to Brian Luquet, Head of Investor Relations and Corporate Development at Fractal. Brian, you may now begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. This afternoon, we issued a press release that outlines the topics we plan to

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.